| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2e7360ed55aaa51bc49eff48a066ae57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e9b1f4bd827b4c8a6b4dc5267888376f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-17023
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48 |
| filingDate |
2022-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1303f32cef9861602808a9767883c06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5ff1796675995c66cb5d547ebfdb3da
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69a980e1b95eb2eb859ce1d76abdfe0f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0a06c39c81725c79f4b5447c67f131cc |
| publicationDate |
2022-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022253272-A1 |
| titleOfInvention |
Multivalent recombinant ace2 and uses thereof |
| abstract |
Recombinant multivalent proteins are provided having two or more angiotensin-converting enzyme 2 (ACE2) fragments and a human immunoglobin Fc domain, wherein the ACE2 fragments are capable of binding to a coronavirus. Within one embodiment the human immunoglobin Fc domain has an N-terminal flexible hinge region which isjoined to the C-terminal ends of a first and a second of the two or more ACE2 fragments. Also provided are expression vectors and host cells for producing the recombinant multivalent proteins, as well as pharmaceutical compositions comprising recombinant multivalent proteins, and methods of using the same (e.g., for the treatment and/or prevention of coronavirus infections). |
| priorityDate |
2021-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |